In this way we can avoid introducing unwanted toxicities and adverse side effects to the body, improving the quality of life of cancer patients and providing hope for a cure to their cancer.

The procedure we are employing is simple, highly-sensitive and very selective.

We determine which patients will benefit from RSK inhibitors using a state-of-the-art platform. The platform is highly quantitative and allows for the measurement of hundreds of genes in a single reaction with nanoscale amounts of genetic material. We are then able to isolate the genetic material from patient tumor samples and apply it to a proprietary list of ~100 selected genes that are known molecular classifiers and drug targets.  We have used this technology extensively in our research over the past three years and we were the first laboratory in Vancouver to publish results using this leading methodology.